新西兰批准昂贵的减重药物Wegovy和Ozempic防治肥胖症和相关健康风险。 New Zealand approves costly weight loss drugs Wegovy and Ozempic to combat obesity and related health risks.

新西兰批准了Wegovy和Ozempic用于处方的减重药物,目的是支持医疗监督的体重管理。 New Zealand has approved weight loss drugs Wegovy and Ozempic for prescription use, aiming to support medically supervised weight management. 这些药物可通过医生处方药的药房提供,可以帮助控制体重和减少糖尿病和心脏病等健康风险。 These drugs, available through pharmacies with a doctor's prescription, can help manage weight and reduce health risks like diabetes and heart disease. 然而,病人可能面临高昂的费用,每月可能高达500美元,因为目前药品不是由政府资助的。 However, patients may face high costs, potentially up to $500 monthly, as the medication is not currently funded by the government.